Search

Displaying results 8791 - 8800 of 10000 in total
  1. Drug

    Ditazole

    go.drugbank.com/drugs/DB08994
    ApprovedWithdrawn

    Additionally, ditazole is a platelet aggregation inhibitor marketed in Spain and Portugal with trade name Ageroplas.

  2. Drug

    Tesofensine

    go.drugbank.com/drugs/DB06156
    Investigational

  3. Drug

    Promestriene

    go.drugbank.com/drugs/DB12487
    Investigational

    It has been also studied in phase III of the clinical trial in the post-operative patients with hypospadias. … Promestriene has been studied in phase IV of the clinical trial on improvement of hormonal cytology, local and systemic climacteric complaints, as well as its endometrial security in patients with vaginitis

  4. Drug

    SLx-4090

    go.drugbank.com/drugs/DB05678
    Investigational

    SLx-4090 is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment of type 2 diabetes.

  5. Drug

    IDM-4

    go.drugbank.com/drugs/DB05438
    Experimental

    IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia.

  6. Drug

    CP-122721

    go.drugbank.com/drugs/DB05421
    Experimental

    CP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory diseases including asthma and irritable bowel syndrome.

  7. Drug

    PGX-100

    go.drugbank.com/drugs/DB06114
    Investigational

    PGX-100 is an intravenous dosage form of modified heparin.

  8. Drug

    Efavaleukin alfa

    go.drugbank.com/drugs/DB16149
    Investigational

    It is under investigation in clinical trial NCT03422627 (Safety and Efficacy of AMG 592 in Subjects With Steroid Refractory Chronic Graft Versus Host Disease). … Efavaleukin alfa is a fusion protein consisting of interleukin mutein fused to the C-terminus of an immunoglobulin G Fc domain by way of a G4S linker.

  9. Drug

    Idraparinux

    go.drugbank.com/drugs/DB06406
    Investigational

    Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events.

  10. Drug

    MPT0B640

    go.drugbank.com/drugs/DB16512
    Investigational

    MPT0B640 was under investigation in clinical trials NCT04526717 for COVID-19 infection and NCT04294875 for locally advanced or metastatic solid malignancies.